Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 10, 2013, Pages 1053-1063

  Viale, Pierluigi ^a   Giannella, Maddalena ^a   Lewis, Russell ^a   Trecarichi, Emanuele Maria ^b   Petrosillo, Nicola ^c   Tumbarello, Mario ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

bloodstream infection; carbapenem resistance; extended spectrum b lactamases; Klebsiella pneumoniae; mortality; risk assessment

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; COLISTIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE;

ANTIMICROBIAL THERAPY; BACTERIAL STRAIN; BLOODSTREAM INFECTION; CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE; DISEASE SEVERITY; DRUG TREATMENT FAILURE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FATALITY; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MORTALITY; MULTIDRUG RESISTANCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INTENSIVE CARE UNITS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MODELS, STATISTICAL; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84886886353     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2013.836057     Document Type: Review

References (65)

1. Hippocrates. Hippocrates Volume II: Prognostic. Jones WHS (Ed.). Harvard University Press, Boston (1923).
2. Braykov NP, Eber MR, Klein EY, Morgan DJ, Laxminarayan R. Trends in resistance to carbapenems and third-generation cephalosporins among clinical isolates of Klebsiella pneumoniae in the United States, 1999-2010. Infect. Control Hosp. Epidemiol. 34(3), 259-268 (2013).
3. Canton R, Akova M, Carmeli Y et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 18(5), 413-431 (2012).
4. Rodriguez-Bano J, Pascual A. Clinical significance of extended-spectrum beta-lactamases. Expert Rev. Anti. Infect. Ther. 6(5), 671-683 (2008).
5. Tumbarello M, Spanu T, Di Bidino R et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob. Agents Chemother. 54(10), 4085-4091 (2010).
6. Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob. Agents Chemother. 52(3), 813-821 (2008).
7. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J. Antimicrob. Chemother. 65(6), 1119-1125 (2011).
8. Tumbarello M, Viale P, Viscoli C et al. Predictors of Mortality in Bloodstream Infections Caused by KPC-producing Klebsiella pneumoniae: Importance of Combination Therapy. Clin. Infect. Dis. (2012) (In Press).
9. Qureshi ZA, Paterson DL, Potoski BA et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob. Agents Chemother. 56(4), 2108-2113 (2012).
10. Petrosillo N, Giannella M, Lewis R, Viale P. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev. Anti. Infect. Ther. 11(2), 159-177 (2013).
11. Trecarichi EM, Cauda R, Tumbarello M. Detecting risk and predicting patient mortality in patients with extended-spectrum beta-lactamase-producing Enterobacteriaceae bloodstream infections. Future Microbiol. 7(10), 1173-1189 (2012).
12. Tumbarello M, Sanguinetti M, Montuori E et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta- lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob. Agents Chemother. 51(6), 1987-1994 (2007).
13. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 18(4), 657-686 (2005).
14. Pitout JD. Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 70(3), 313-333 (2010).
15. Tumbarello M, Trecarichi EM, Bassetti M et al. Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob. Agents Chemother. 55(7), 3485-3490 (2011).
16. Schwaber MJ, Navon-Venezia S, Schwartz D, Carmeli Y. High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 49(5), 2137-2139 (2005).
17. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J. Antimicrob. Chemother. 60(5), 913-920 (2007).
18. Pena C, Pujol M, Ardanuy C et al. An outbreak of hospital-acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum beta-lactamase. J. Hosp. Infect. 47(1), 53-59 (2001).
19. Marra AR, Wey SB, Castelo A et al. Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum beta-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence. BMC Infect. Dis. 6, 24 (2006).
20. Kang CI, Kim SH, Kim DM et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol. 25(10), 860-867 (2004).
21. Tuon FF, Kruger M, Terreri M, Penteado-Filho SR, Gortz L. Klebsiella ESBL bacteremia-mortality and risk factors. Braz. J. Infect. Dis. 15(6), 594-598 (2011).
22. Tumbarello M, Spanu T, Sanguinetti M et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob. Agents Chemother. 50(2), 498-504 (2006).
23. Mosqueda-Gomez JL, Montano-Loza A, Rolon AL et al. Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study. Int. J. Infect. Dis. 12(6), 653-659 (2008).
24. Ariffin H, Navaratnam P, Mohamed M et al. Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia. Int. J. Infect. Dis. 4(1), 21-25 (2000).
25. Murphy CN, Clegg S. Klebsiella pneumoniae and type 3 fimbriae: nosocomial infection, regulation and biofilm formation. Future Microbiol. 7(8), 991-1002 (2012).
26. Yu VL, Hansen DS, Ko WC et al. Virulence characteristics of Klebsiella and clinical manifestations of K. pneumoniae bloodstream infections. Emerg. Infect. Dis. 13(7), 986-993 (2007).
27. Apisarnthanarak A, Kiratisin P, Mundy LM. Predictors of mortality from community-onset bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol. 29(7), 671-674 (2008).
28. Anderson DJ, Engemann JJ, Harrell LJ, Carmeli Y, Reller LB, Kaye KS. Predictors of mortality in patients with bloodstream infection due to ceftazidime-resistant Klebsiella pneumoniae. Antimicrob. Agents Chemother. 50(5), 1715-1720 (2006).
29. Kim BN, Woo JH, Kim MN, Ryu J, Kim YS. Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. J. Hosp. Infect. 52(2), 99-106 (2002).
30. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin. Infect. Dis. 39(1), 31-37 (2004).
31. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J. Antimicrob. Chemother. 67(12), 2793-2803 (2012).
32. Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. beta-Lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin. Infect. Dis. 54(2), 167-174 (2012).
33. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin. Infect. Dis. 53(1), 60-67 (2011).
34. Srinivasan A, Patel JB. Klebsiella pneumoniae carbapenemase-producing organisms: an ounce of prevention really is worth a pound of cure. Infect. Control Hosp. Epidemiol. 29(12), 1107-1109 (2008).
35. Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein. Antimicrob. Agents Chemother. 41(3), 563-569 (1997).
36. Orsi GB, Garcia-Fernandez A, Giordano A et al. Risk factors and clinical significance of ertapenem-resistant Klebsiella pneumoniae in hospitalised patients. J. Hosp. Infect. 78(1), 54-58 (2011).
37. Capone A, Giannella M, Fortini D, Giordano A, Meledandri M, Ballardini M, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin. Microbiol. Infect. 19(1), E23-30 (2013).
38. Sidjabat HE, Silveira FP, Potoski BA et al. Interspecies spread of Klebsiella pneumoniae carbapenemase gene in a single patient. Clin. Infect. Dis. 49(11), 1736-1738 (2009).
39. Kwak YG, Choi SH, Choo EJ et al. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb. Drug Resist. 11(2), 165-169 (2005).
40. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob. Agents Chemother. 52(3), 1028-1033 (2008).
41. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect. Control Hosp. Epidemiol. 29(12), 1099-1106 (2008).
42. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect. Control Hosp. Epidemiol. 30(12), 1180-1185 (2009).
43. Borer A, Saidel-Odes L, Eskira S et al. Risk factors for developing clinical infection with carbapenem-resistant Klebsiella pneumoniae in hospital patients initially only colonized with carbapenem-resistant K pneumoniae. Am. J. Infect. Control 40(5), 421-425 (2012).
44. Borer A, Saidel-Odes L, Riesenberg K et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect. Control Hosp. Epidemiol. 30(10), 972-976 (2009).
45. Kalpoe JS, Sonnenberg E, Factor SH et al. Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl. 18(4), 468-474 (2012).
46. Tumbarello M, Viale P, Viscoli C et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin. Infect. Dis. 55(7), 943-950 (2012).
47. Zarkotou O, Pournaras S, Tselioti P et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin. Microbiol. Infect. 17(12), 1798-1803 (2011).
48. Nguyen M, Eschenauer GA, Bryan M, O'Neil K, Furuya EY, Della-Latta P, et al. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn. Microbiol. Infect. Dis. 67(2), 180-184 (2010).
49. Neuner EA, Yeh JY, Hall GS et al. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn. Microbiol. Infect. Dis. 69(4), 357-362 (2011).
50. Sbrana F, Malacarne P, Viaggi B et al. Carbapenem-sparing antibiotic regimens for infections caused by KPC-producing Klebsiella pneumoniae in Intensive Care Unit. Clin. Infect. Dis. doi: 10.1093/cid/cis969 (2012).
51. Grgurich PE, Hudcova J, Lei Y, Sarwar A, Craven DE. Diagnosis of ventilator-associated pneumonia: controversies and working toward a gold standard. Curr. Opin. Infect. Dis. 26(2), 140-150 (2013).
52. Daikos GL, Petrikkos P, Psichogiou M et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob. Agents Chemother. 53(5), 1868-1873 (2009).
53. Mouloudi E, Protonotariou E, Zagorianou A et al. Bloodstream infections caused by metallo-beta-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect. Control Hosp. Epidemiol. 31(12), 1250-1256 (2010).
54. Ben-David D, Kordevani R, Keller N et al. Outcome of carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Clin. Microbiol. Infect. 18(1), 54-60 (2012).
55. Hussein K, Raz-Pasteur A, Finkelstein R et al. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae. J Hosp. Infect. 83(4), 307-313 (2013).
56. Bartoletti M, Lewis RE, Tumietto F et al. Prospective, Cross-Sectional Observational Study of Hospitalized Patients Colonized with Carbapenemase- Resistant Klebsiella pneumoniae (CR-KP). Presented at: 23rd European Conference on Clinical Microbiology and Infectious Diseases. Berlin, Germany, 27-30 April 2013.
57. Bleumin D, Cohen MJ, Moranne O et al. Carbapenem-resistant Klebsiella pneumoniae is associated with poor outcome in hemodialysis patients. J. Infect. 65(4), 318-325 (2012).
58. Flowers CR, Seidenfeld J, Bow EJ et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 31(6), 794-810 (2013).
59. Moons KG, Altman DG, Vergouwe Y, Royston P. Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ 338, b606 (2009).
60. Toll DB, Janssen KJ, Vergouwe Y, Moons KG. Validation, updating and impact of clinical prediction rules: a review. J. Clin. Epidemiol. 61(11), 1085-1094 (2008).
61. Bosco JL, Silliman RA, Thwin SS et al. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J. Clin. Epidemiol. 63(1), 64-74 (2010).
62. Altman DG, Vergouwe Y, Royston P, Moons KG. Prognosis and prognostic research: validating a prognostic model. BMJ 338, b605 (2009).
63. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am. J. Med. 91(3B), 72S-75S (1991).
64. Daikos GL, Markogiannakis A, Souli M, Tzouvelekis LS. Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective. Expert Rev. Anti. Infect. Ther. 10(12), 1393-1404 (2012).
65. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis.9(4), 228-236 (2009).